Teva Reports Strong Second Quarter 2015 Results and Raises Guidance for Full-Year 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
JPMorgan Reinstates Teva Pharma (TEVA) at Overweight
August 3, 2015 8:40 AM EDTJPMorgan reinstated coverage on Teva Pharma (NYSE: TEVA) with an Overweight rating and a price target of $82.00 (prior $70.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $69.02 yesterday.
... MoreTeva Pharma (TEVA) Tops Q2 EPS by 12c; Boosts FY15 EPS Outlook
July 30, 2015 7:06 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $1.43, $0.12 better than the analyst estimate of $1.31. Revenue for the quarter came in at $4.97 billion versus the consensus estimate of $4.9 billion.
Teva Pharma sees FY2015 EPS of $5.15-$5.40, versus prior guidance of $5.05-$5.35 and the consensus of... More
